John L. Marshall, MD

Articles

Patient Profile 2: A 35-Year-Old Man With Oligometastatic Colorectal Cancer

April 23rd 2024

Benjamin A. Weinberg, MD, presents the case of a 35-year-old man with oligometastatic disease, and the panel provides insights on treatment decisions.

Myths Surrounding Liquid Biopsy and ctDNA Testing for MRD

April 15th 2024

Pashtoon Murtaza Kasi, MD, MS, emphasizes key aspects of liquid biopsy and ctDNA testing in the MRD treatment landscape.

BESPOKE CRC: Study of ctDNA-Guided Therapy in Colorectal Cancer

April 15th 2024

Pashtoon Murtaza Kasi, MD, MS, reviews data from the BESPOKE CRC study, highlighting overall results and patient-reported outcomes.

Colorectal Cancer: Updates from the GALAXY Arm in CIRCULATE-Japan

April 9th 2024

Focusing on the GALAXY arm in the CIRCULATE-Japan study, experts on colorectal cancer discuss how recent data are informing the evolving treatment landscape.

Patient Profile: A 52-Year-Old Woman With Colorectal Cancer

April 1st 2024

John L. Marshall, MD, presents the case of a 52-year-old woman with mid-rectal carcinoma, and the panel offers its initial impressions.

Evolution of MRD Testing in Colorectal Cancer

April 1st 2024

The panel discusses how MRD testing has evolved as a clinical tool in colorectal cancer, highlighting the phase 2/3 COBRA study and its implications.

Practical Considerations in MRD Testing in CRC

March 25th 2024

Experts on colorectal cancer discuss practical considerations related to MRD testing, highlighting strategies to navigate potential challenges.

Colorectal Cancer: MRD Testing in the Community Setting

March 25th 2024

Pashtoon Murtaza Kasi, MD, MS, discusses MRD testing practices in the community oncology setting and provides recommendations on the integration of MRD testing into clinical practice.

Testing for MRD in Colorectal Cancer

March 18th 2024

Focusing on the adjuvant setting, the expert panel discusses the timing and frequency of MRD testing in patients with colorectal cancer.

MRD Testing Platforms in Colorectal Cancer

March 18th 2024

Colorectal cancer specialists discuss MRD testing platforms and how to choose among the available testing assays.

When is MRD Testing Performed in Colorectal Cancer Treatment?

March 11th 2024

Experts on colorectal cancer discuss the timing of testing for minimal residual disease in the treatment journey.

Treating Colorectal Cancer: Overview of MRD Testing and ctDNA

March 11th 2024

A panel medical oncologists provide an overview of circulating tumor DNA and its role in MRD (minimal residual disease) testing in the treatment of patients with colorectal cancer.

Dr Marshall on the FDA Approval of Fruquintinib in mCRC

November 9th 2023

John Lindsay Marshall, MD, discusses the significance of the FDA approval of fruquintinib (Fruzaqla) in patients with metastatic colorectal cancer.

Dr Marshall on Key Takeaways from the 2023 SOGO Annual Meeting in GI Cancer

May 8th 2023

John L. Marshall, MD, discusses the key takeaways from the 8th Annual School of Gastrointestinal Oncology® and remaining unmet needs for patients with metastatic colorectal cancer.

Dr. Marshall on Genetic Testing in Gastrointestinal Cancer

October 5th 2022

John L. Marshall, MD, discusses the evolution of genetic testing in gastrointestinal cancer.

Dr. Marshall on Utilizing Precision Medicine in Bile Duct Cancer

March 31st 2022

John L. Marshall, MD, discusses potential next steps with research in bile duct cancer.

Dr. Marshall on the Results of the DESTINY-Gastric02 Trial in Gastric/GEJ Cancer

October 25th 2021

John L. Marshall, MD, discusses the results of the phase 2 DESTINY-Gastric02 trial in HER2-positive gastric and gastroesophageal junction cancers.

Dr. Marshall on Key Data from the DESTINY-Gastric02 Trial in HER2+ Gastric Cancer

October 15th 2021

John L. Marshall, MD, discusses key findings from the phase 2 DESTINY-Gastric02 trial examining fam-trastuzumab deruxtecan-nxki in patients with HER2-positive gastric cancer.

Dr. Marshall on the Importance of Molecular Profiling When Utilizing Precision Medicine

September 20th 2021

John L. Marshall, MD, discusses the importance of molecular profiling when utilizing precision medicine.

Dr. Marshall on Considerations for Third-Line Therapeutic Options in CRC

September 14th 2021

John L. Marshall, MD, discusses factors to consider in the third-line treatment setting for patients with colorectal cancer.